Enanta Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2011
Cash & Equivalents	89.36	47.96	57.81	87.74	51.84	64.51	66.28	17.19	22.33	31.14	Upgrade
Short-Term Investments	284.52	205.24	186.8	299.52	284.01	244.83	157.99	193.51	123.48	60.07	Upgrade
Cash & Cash Equivalents	373.88	253.2	244.61	387.26	335.84	309.34	224.28	210.69	145.81	91.2	Upgrade
Cash Growth	47.66%	3.51%	-36.84%	15.31%	8.57%	37.93%	6.45%	44.49%	59.88%	-10.51%	Upgrade
Receivables	8.61	20.32	23.58	23.49	51.31	67.21	10.61	12.84	15.72	4.49	Upgrade
Other Current Assets	40.3	38.2	50.84	26.09	14.69	3.85	2.93	8.62	9.11	12.28	Upgrade
Total Current Assets	422.79	311.71	319.02	436.84	401.85	380.39	237.82	232.16	170.64	107.98	Upgrade
Property, Plant & Equipment	34.71	29.75	10.65	15.62	10.93	8.37	8.05	8	5.89	1.8	Upgrade
Long-Term Investments	0	29.29	108.42	32.63	65.01	16.39	70.04	32.12	64.24	41	Upgrade
Other Long-Term Assets	4.77	4.66	0.7	1.05	12.04	9.08	10.73	9	5.25	4.63	Upgrade
Total Long-Term Assets	39.48	63.7	119.77	49.3	87.98	33.84	88.82	49.12	75.37	47.44	Upgrade
Total Assets	462.28	375.41	438.79	486.13	489.83	414.23	326.64	281.28	246.01	155.42	Upgrade
Accounts Payable	4.1	6	9.54	5.74	6.69	4.75	3.71	3.38	1.54	1.87	Upgrade
Current Debt	5.28	2.89	4.2	4.26	0	0	0	0	0	0	Upgrade
Other Current Liabilities	53.42	20.94	22.43	14.16	15.92	11.28	17.27	4.51	5.16	2.87	Upgrade
Total Current Liabilities	62.79	29.83	36.17	24.16	22.61	16.03	20.98	7.89	6.7	4.75	Upgrade
Long-Term Debt	21.24	22.37	1.13	3.84	0	0	0	0	0	0	Upgrade
Other Long-Term Liabilities	161.52	1.88	2.06	2.56	4.73	4.52	3.98	3.45	3.15	2.02	Upgrade
Total Long-Term Liabilities	182.75	24.25	3.19	6.4	4.73	4.52	3.98	3.45	3.15	2.02	Upgrade
Total Liabilities	245.54	54.08	39.36	30.55	27.34	20.55	24.96	11.34	9.86	6.76	Upgrade
Total Debt	26.51	25.26	5.33	8.1	0	0	0	0	0	0	Upgrade
Debt Growth	4.95%	374.07%	-34.20%	-	-	-	-	-	-	-	Upgrade
Retained Earnings	-207	-73.18	48.58	127.57	163.74	117.36	45.36	27.65	5.98	-73.01	Upgrade
Comprehensive Income	-1.17	-3.72	-0.38	0.84	0.15	-0.4	-0.11	0.02	0.03	-0.1	Upgrade
Shareholders' Equity	216.74	321.33	399.43	455.58	462.49	393.68	301.68	269.94	236.16	148.65	Upgrade
Net Cash / Debt	347.37	227.94	239.28	379.16	335.84	309.34	224.28	210.69	145.81	91.2	Upgrade
Net Cash / Debt Growth	52.40%	-4.74%	-36.89%	12.90%	8.57%	37.93%	6.45%	44.49%	59.88%	-10.51%	Upgrade
Net Cash Per Share	16.57	11.06	11.86	19.01	16.02	14.98	11.56	10.96	7.56	4.75	Upgrade
Working Capital	360	281.89	282.85	412.68	379.24	364.36	216.84	224.27	163.94	103.23	Upgrade
Book Value Per Share	10.34	15.60	19.80	22.85	23.62	20.45	15.82	14.26	12.65	8.10	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).